Cadralazine Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Cadralazine is a vasodilatory antihypertensive reportedly better-tolerated and
longer-acting than hydralazine. It is useful as a second-line treatment in the management
of hypertension.
Weltgesundheitsorganisation (WHO)
Cadralazine, a peripheral vasodilator, was introduced in 1989 for
the treatment of arterial hypertension.In 1992, its association with serious side
effects led to the refusal of registration in Norway. Animal experiments have
demonstrated drug-related impairment of thyroid function as well as potential carcinogenicity and genotoxicity. It remains available for treatment of hypertension
in Italy.
Cadralazine Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
